

ONWARD & UPWARD

Atlas' New Funds: **\$750M** ready to back new and emerging biotechs

\$450M Fund XIII to build breakthrough biotech startups

\$300M Opportunity Fund II to invest growth capital into our portfolio

2022 HEADLINE NEWS

nimbus
THERAPEUTICS

TAKEDA ACQUIRES NIMBUS' TYK2 PROGRAM FOR \$4B + POTENTIAL MILESTONES

(vigil)
NEURO

VIGL raises \$173M via IPO & FOPO

Third Harmonic Bio

THRD raises \$213M IPO

discomedicine

Goes public via reverse merger and nets \$175M

akero

Phase 2b study in NASH patients met primary endpoints

Day One
BIOPHARMACEUTICALS


Positive initial data from pivotal Phase 2 trial in patients with pLGG

Replimune


Positive initial data from Anti-PD1 failed melanoma cohort of the IGYTE clinical trial

ATLAS PORTFOLIO LEADERS


MEET SOME OF OUR NEWEST CEOs




Bertrand Damour
CEO
Pheon Therapeutics



Raj Devraj, PhD
President and CEO
Rectify Pharmaceuticals




Jodie Morrison
Acting CEO
Q32 Bio




Mark Pruzanski, MD
Chairman and CEO
Versanis Bio

INTRODUCING SOME OF OUR EIRs



Judy Dunn
Entrepreneur-in-Residence
Atlas



Alex Lugovskoy, PhD
Entrepreneur-in-Residence and CEO
Diagonal Therapeutics



Vishal Patel, PhD
Entrepreneur-in-Residence and CEO
Atlas NewCo



Bernard Ravina, MD
Entrepreneur-in-Residence
Atlas



James Thornton
Entrepreneur-in-Residence
Atlas



Jeff Albers
Venture Partner
Atlas

NEW STARTUP SPOTLIGHTS

CHECK OUT SOME OF OUR RECENTLY LAUNCHED PORTFOLIO COMPANIES

3 COMPANIES RAISED **>\$250M**

matchpoint
THERAPEUTICS

PHEON
THERAPEUTICS

TRIANA
Biomedicines

CLINICAL UPDATES

23 COMPANIES WITH NEW CLINICAL STUDY INITIATIONS/DATA IN 2022

PHASE 1

ikena
ONCOLOGY

k36
therapeutics

kinaset
Therapeutics

KYMERA

OBSIDIAN
THERAPEUTICS

sionna

SURFACE
ONCOLOGY

xilio
THERAPEUTICS

PHASE 2

akero

AVROBIO

discomedicine

Dyne
THERAPEUTICS

F-star
THERAPEUTICS

Intellia
THERAPEUTICS

Larimar
Therapeutics

nimbus
THERAPEUTICS

Q32 BIO

Replimune

synlogic

(vigil)
NEURO

Versanis

PHASE 3

Day One
BIOPHARMACEUTICALS

SPERO
THERAPEUTICS

FINANCINGS & BD

ADVANCING THERAPEUTIC PROGRAMS WITH NEW CAPITAL AND STRATEGIC COLLABORATIONS

6

PUBLIC COMPANIES RAISED >\$1.1B IN FOLLOW-ON FINANCINGS

akero

Day One
BIOPHARMACEUTICALS

Intellia
THERAPEUTICS

KYMERA

Replimune

(vigil)
NEURO

4

PRIVATE COMPANIES RAISED >\$360M IN SERIES B ROUNDS

ARKUDA
THERAPEUTICS

be
BIOPHARMA

remix
therapeutics

sionna

6

COMPANIES ESTABLISHED SIGNIFICANT COLLABORATIONS WITH >\$4.1B TOTAL POTENTIAL DISCLOSED DEAL VALUE

be
BIOPHARMA

RESILIENCE
BIOTECHNOLOGIES INC

HOTSPOT
THERAPEUTICS

abbvie

nimbus
THERAPEUTICS

Lilly

Q32 BIO

HORIZON

remix
therapeutics

Johnson & Johnson

SCORPION

AstraZeneca

ATLAS COMMUNITY HIGHLIGHTS

Atlas' exclusive online community for portfolio company leadership convened executives on events including a State of the State of Biotech Markets and function-focused C-Suite Pods throughout the year

NAUTILUS
BY ATLAS VENTURE

Atlas Companies are Hiring

Visit our careers page to learn more

VIEW CAREERS

Science2Startup is Returning

Contact info@science2startup.com for more information

GET INVOLVED

ATLAS REVIEWS & PERSPECTIVES

2022 Year In Review

Our annual presentation on the year in biotech presented by Bruce Booth

WATCH RECORDING

How Remix Built a Science-Driven and Transparent Culture

From the Trenches post by Peter Smith, CEO, Remix Therapeutics

READ ARTICLE

Surprising Resilience of Private VC-Backed Biotech Markets

LifeSciVC post by Bruce Booth

READ ARTICLE

The Courage of Patients in Phase 1 Cancer Trials

From the Trenches post by Rene Russo, CEO, Xilio Therapeutics

READ ARTICLE